Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

31 valent pneumococcal conjugate vaccine

Vaccine · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides · developed by Vaxcyte

Phase 3 Most advanced trial
PCVX Developer
2 Registered trials

What is 31 valent pneumococcal conjugate vaccine?

31 valent pneumococcal conjugate vaccine (VAX-31) is administered by intramuscular injection into the deltoid muscle at a 0.5 mL dose. It is studied for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Targets
Streptococcus pneumoniae capsular polysaccharides (antigen)
Mechanism
Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides
Therapy area
Infectious disease
Developer
Vaxcyte, Inc. (PCVX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07425392 Phase 3 Pneumococcal Vaccines Active not recruiting PCVX
NCT07284654 Phase 3 Pneumococcal Disease Completed PCVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pneumococcal VaccinesPneumococcal Disease

More from Vaxcyte

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PCVX page.

Follow PCVX, the company behind 31 valent pneumococcal conjugate vaccine

See PCVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PCVX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.